Stagezero Life Sciences (OTCMKTS:SZLSF) and Senestech (NASDAQ:SNES) Financial Comparison

Senestech (NASDAQ:SNES) and Stagezero Life Sciences (OTCMKTS:SZLSF) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.

Insider and Institutional Ownership

5.2% of Senestech shares are held by institutional investors. 5.3% of Senestech shares are held by company insiders. Comparatively, 2.5% of Stagezero Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Senestech and Stagezero Life Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senestech	1	1	0	1	2.33
Stagezero Life Sciences	0	0	0	0	0.00

Risk and Volatility

Senestech has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Stagezero Life Sciences has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500.

Earnings and Valuation

This table compares Senestech and Stagezero Life Sciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senestech	$1.86 million	5.61	-$6.18 million	($3.65)	-0.55
Stagezero Life Sciences	N/A	N/A	N/A	($0.01)	-0.05

Stagezero Life Sciences has lower revenue, but higher earnings than Senestech. Senestech is trading at a lower price-to-earnings ratio than Stagezero Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Senestech and Stagezero Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Senestech	-253.54%	-98.35%	-73.17%
Stagezero Life Sciences	N/A	N/A	N/A

Summary

Senestech beats Stagezero Life Sciences on 6 of the 11 factors compared between the two stocks.

About Senestech

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

About Stagezero Life Sciences

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual’s current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman’s risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.